Oncoinvent ASA Cash Flow Statement

Financials in millions NOK. Fiscal year is January - December.

Millions NOK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-155.07	-140.2	-143.62	-106.28	-
Depreciation & Amortization	11.25	14.56	11.26	7.99	-
Stock-Based Compensation	3.87	-2.19	4.41	-4.44	-
Other Operating Activities	18.15	-0.9	-5.74	6.85	-
Change in Accounts Payable	-9.6	23.6	4.69	8.26	-
Change in Other Net Operating Assets	1.52	17.19	-9.11	-1.56	-
Operating Cash Flow	-129.87	-87.94	-138.11	-89.19	-
Capital Expenditures	-0.12	-1.8	-26.83	-3.98	-
Sale of Property, Plant & Equipment	-	0.77	-	-	-
Other Investing Activities	3.49	1.34	4.41	-	-
Investing Cash Flow	3.37	0.31	-22.42	-3.98	-
Long-Term Debt Repaid	-2.52	-4.11	-3.53	-3.08	-
Net Debt Issued (Repaid)	-2.52	-4.11	-3.53	-3.08	-
Issuance of Common Stock	141	207.99	0.51	0.25	-
Other Financing Activities	-19.27	-12.66	-0.34	-0.09	-
Financing Cash Flow	119.21	191.21	-3.37	-2.93	-
Miscellaneous Cash Flow Adjustments	51.27	-	-	0.09	-
Net Cash Flow	43.98	103.57	-163.9	-96.01	-
Free Cash Flow	-129.99	-89.75	-164.94	-93.17	-
Free Cash Flow Margin	-463.11%	-1107.55%	-2848.72%	-1482.94%	-
Free Cash Flow Per Share	-1.05	-97.29	-848.27	-480.45	-
Cash Interest Paid	-	0.08	0.34	0.09	-
Levered Free Cash Flow	-87.57	-36.83	-110.11	-52.26	-
Unlevered Free Cash Flow	-87.04	-36.78	-110.1	-52.25	-
Change in Working Capital	-8.08	40.79	-4.42	6.7	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.